Citius Oncology Inc (CTOR) Stock Price, Quote & News

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 967 6677

Address:

11 Commerce Drive, First Floor, Cranford, United States

ImmxBeliever Jan. 17 at 4:37 AM

$CTOR $CTXR Where is @sushifishman

0 · Reply

SweStonk Jan. 16 at 5:07 PM

$CTXR Mazur completely back stabbed his investors here. He spun off the only value left and diluted EVERYONE to oblivion. Even tho he PROMISED and said: I will spin off lymphir so we wont need to dilute CTXR. It was a BIG lie and he diluted and destroyed CTXRs value with 98% and still counting. Not a single dollar went to our main asset ML and he just put it into the ground. Dont fool yourself it will be any different in CTOR. He have blown up the numbers big time and competition with better efficiancy/treatment make not even close to the numbers Mazur speak of. So many lies from this management. They even lied about the launch. They lied about distribution. They lied about ML being a billion dollar treatment(it is worth ZERO cause nobody want to buy it) Both CTXR and $CTOR will go bankrupt. Lawsuits are flying against Mazur and this time I believe the ambulance chasers actually have a real case. DONT FEED this conman I hope you all find something that make up for the loss. ❤️

1 · Reply

donein12 Jan. 16 at 10:13 AM

$CTOR F/Y/I NEW YORK, Jan. 5, 26 /PRNewswire/ - Purcell & Lefkowitz LLP announces that it is investigating Citius Oncology, Inc. ( CTOR) on behalf of the co's SH's.The investigation seeks to determine whether Citius Oncology's directors breached their fiduciary duties in connection with recent corporate actions. If you are a SH of Citius Oncology and are interested in obtaining add'l information about your rights and options, please visit us at: https://pjlfirm.com/citius-oncology/ You may contact Robert H. Lefkowitz, Esq. via email at [email protected] or by telephone at 212-725-1000. One of our attorneys will personally speak with you about the case at no cost or obligation. Purcell & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct. For more information about the firm and its attorneys, visit https://pjlfirm.com. SOURCE Purcell & Lefkowitz LLP

1 · Reply

yellowjacker Jan. 15 at 10:51 PM

$CTXR Ran some questions by Gemi today that put $CTXR and $CTOR in their right perspective. I have been concerned about trying to figure out how both interact with each other. I am holding only $CTXR shares and have worried that $CTOR could drag $CTXR down. Gemi made a good case that $CTXR is the main player or driver holding 78% of $CTOR shares. That the work horse will be Hado-Lido to save the day for the $CTXR and $CTOR if needed. With Hado-Lido having superior results in phase 2 trials, as the only prescription option coming to market, it will generate huge profits due to the 10 million people just in the United States needing a better treatment. With cash runs getting low on both $CTXR and $CTOR, Gemi sees a high probability that a license agreement will be made soon and tells me to look for the next quartly earning for a annoucement for most likely a licensing deal with upfront cash to help cash run and a royalty package coming from one of the top hemorrhoid company.

2 · Reply

donein12 Jan. 13 at 7:20 PM

$CTOR May be a rocky day for the stock market tomorrow since belief is the SCOTUS will rule on Trumps tariffs. Market today indicates the SCOTUS will rule against Trump! If so trouble. Just have to wait and see if there is a ruling tomorrow or not.

0 · Reply

TwongStocks Jan. 13 at 1:28 PM

$CTOR Notice of Effectiveness filed for the Jan 5 warrant registration https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&filenum=333-292577 The S-3 registration filed on Jan 5 registered the warrants and pre-funded warrants from CTOR's December offering. Per the purchase agreement, CTOR is under a lockup which prevents them from entering into any new offerings for two months. The lockup expires "60 days following after the effective date of the registration statement". With a Jan 12 effective date, CTOR's lockup expires March 13. Per the 10-K, current cash runway for CTOR and $CTXR is through March 2026 (screenshot). CTOR is under a lockup through March 13 and cannot do any offerings until then. CTXR is currently under a lockup through Jan 19, ninety days after their Oct 21 offering. If they need to raise cash before March 13, it will likely come via CTXR.

1 · Reply

SKEETER_1 Jan. 13 at 12:35 PM

$CTOR the current class action lawsuit against CTOR has a lot more traction then the last ones.i dont think they're accepting small hush money this time

0 · Reply

SKEETER_1 Jan. 13 at 12:31 PM

$CTOR another dilution just around the corner. Then delisting and reverse split. There'll never be any lymphir sales. Scam company

0 · Reply

donein12 Jan. 12 at 2:00 PM

$CTOR They claim to have launched Lymphir on 12/1/2025,however as of today 1/12/2026 there has not been any guidance how the product was received in the market place. Kinda makes me wonder how well it is doing especially with Mazur heading the charge.

0 · Reply

SweStonk Jan. 9 at 1:31 PM

$CTOR $CTXR time for rebound? Oh wait we have ANOTHER dilution hanging over our head! Sorry I meant 2 more Very goodjob Mazur. You do know as a CEO you are supposed to make SP go up and not down? You are supposed to create value not destroy it.

1 · Reply

Market Cap	91.58M
Revenue (ttm)	0.00
Net Income (ttm)	-24.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.30

Volume	86,600
Avg Vol	518,452
Day's Range	N/A - N/A
Shares Out	84.80M
Stochastic %K	5%
Beta	3.09
Analysts	Strong Sell
Price Target	$6.00